Hemato Oncology Testing Market Report Scope & Overview:

The Hemato Oncology Testing Market was valued at USD 4.29 Billion in 2025 and is expected to reach USD 15.36 Billion by 2035, growing at a CAGR of 13.67% from 2026 to 2035.

The global hemato oncology testing market is experiencing robust double-digit growth driven by the rising prevalence of hematologic malignancies including leukemia, lymphoma, myeloproliferative neoplasms, and multiple myeloma, the accelerating adoption of precision medicine and companion diagnostics that require molecular characterization of tumor biology before targeted therapy selection, and the transformative impact of next-generation sequencing and liquid biopsy technologies on diagnostic sensitivity and treatment monitoring capability. Hematologic cancers collectively account for approximately 10% of all new cancer diagnoses in the United States annually, with non-Hodgkin lymphoma alone responsible for more than 500,000 new global diagnoses each year creating the most commercially significant single diagnostic volume stream in the hematologic oncology testing market.

In 2023, the U.S. FDA approved QIAGEN's Thera screen FGFR2 RGQ RT-PCR Kit for detection of genetic mutations in leukemia, providing regulatory validation for molecular PCR-based companion diagnostics in hematologic malignancy that supports targeted therapy prescribing decisions and demonstrates the regulatory pathway maturation that sustains companion diagnostic market investment. The approval reflects the growing commercial alignment between molecular diagnostic platforms and targeted oncology therapeutics whose prescribing requires confirmed genetic mutation status that only validated companion diagnostic testing can provide.

Market Size and Forecast:

• Market Size in 2026E: USD 4.88 Billion

• Market Size by 2035: USD 15.36 Billion

• CAGR: 13.67% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

Hemato Oncology Testing Market Trends:

• Growing adoption of comprehensive genomic profiling is expanding the use of multi-gene NGS panels for precision diagnosis and targeted therapy selection in hematologic malignancies

• Minimal residual disease (MRD) monitoring is becoming a standard practice for assessing treatment response and guiding therapy decisions using highly sensitive PCR and NGS technologies

• Increasing development of companion diagnostics for CAR-T cell therapies is supporting patient selection and personalized treatment across leukemia, lymphoma, and multiple myeloma

• AI-powered digital pathology and flow cytometry analysis are improving diagnostic accuracy, workflow efficiency, and standardization in hematopathology laboratories

• Expansion of liquid biopsy technologies is enabling non-invasive monitoring of disease progression, clonal evolution, and treatment response through circulating tumor DNA analysis

U.S. Hemato Oncology Testing Market Outlook:

The U.S. Hemato Oncology Testing Market was valued at approximately USD 1.19 Billion in 2025 and is expected to reach approximately USD 4.25 Billion by 2035, growing at a CAGR of approximately 13.70%.

The United States is the world's most commercially significant hemato oncology testing market, housing the global headquarters of Illumina, Thermo Fisher Scientific, QIAGEN, Roche Diagnostics, and Guardant Health whose molecular oncology diagnostic platform revenues define commercial benchmarks. The U.S. FDA's regulatory leadership in companion diagnostic approvals, with over 50 companion tests for hematologic malignancies approved, creates the most mature regulatory adoption framework globally. Medicare's reimbursement for FDA-approved molecular diagnostic tests, private insurer coverage expansion for NGS-based oncology testing, and CMS's MolDX molecular diagnostic programme collectively create structured reimbursement that sustains commercial diagnostic investment.

In 2024, Illumina's TruSight Oncology 500 NGS panel achieved expanded clinical adoption across U.S. comprehensive cancer centres as a comprehensive companion diagnostic platform for identifying genetic mutations across leukemia and lymphoma indications, supporting precision oncology prescribing across the expanding portfolio of targeted therapies whose approved labels require companion diagnostic mutation confirmation.

Hemato Oncology Testing Market Segment Analysis:

• By Cancer Type, the Lymphoma segment dominated the Hemato Oncology Testing Market with approximately 45.28% share in 2025, while the Leukemia segment is the fastest growing.

• By Product, the Services segment dominated the Hemato Oncology Testing Market with approximately 60.14% share in 2025, while the Assay Kits and Reagents segment is the fastest growing.

• By Technology, the PCR segment dominated the Hemato Oncology Testing Market with approximately 32.14% share in 2025, while the NGS segment is the fastest growing.

• By End-Use, the Hospitals segment dominated the Hemato Oncology Testing Market with approximately 74.55% share in 2025, while the Academic & Research Institutes segment is the fastest growing.

By Cancer Type, lymphoma dominates, leukemia grows fastest

Lymphoma retained the dominant cancer type position with approximately 45.28% of the hemato oncology testing market in 2025. Non-Hodgkin lymphoma's extraordinary diagnostic complexity, encompassing more than 60 recognized molecular subtypes including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and T-cell lymphoma variants whose treatment selection requires molecular subtype characterization that comprehensive diagnostic testing provides, creates the highest per-diagnosis testing value of any hematologic malignancy category. The approved CAR-T cell therapies Yescarta and Kymriah for relapsed or refractory diffuse large B-cell lymphoma require companion diagnostic characterization of treatment eligibility that creates mandatory companion diagnostic testing associated with each CAR-T treatment decision. The growing targeted therapy portfolio for lymphoma indications, including BTK inhibitors, BCL-2 inhibitors, and bispecific antibodies whose prescribing benefits from molecular characterization, sustains above-average diagnostic testing value per lymphoma patient across treatment lines.

Leukemia is the fastest growing cancer type segment because the expanding companion diagnostic approval landscape for targeted leukemia therapies, including FLT3 inhibitors in AML, BCR-ABL inhibitors in CML and ALL, and IDH1/2 inhibitors in AML, creates mandatory companion diagnostic testing at every treatment line change decision point. Each new targeted leukemia therapy approval that requires companion diagnostic confirmation of actionable mutation status creates a structured testing requirement whose commercial value scales with the approved indication's patient population. The adoption of ultra-sensitive PCR and NGS-based MRD monitoring in CML, ALL, and AML treatment protocols creates a longitudinal testing requirement where each treated patient generates multiple testing episodes per year across the treatment and remission monitoring continuum.

By Product, services dominate, assay kits and reagents grow fastest

Services retained the dominant product position with approximately 60.14% of the hemato oncology testing market in 2025. The technical complexity of comprehensive genomic profiling using NGS, the bioinformatics infrastructure required for variant classification in hematologic malignancy genes, and the regulatory validation burden of molecular oncology testing create barriers to in-house test provision that drive systematic outsourcing to specialty reference laboratories. Each hospital oncology programme whose molecular pathology infrastructure cannot provide the analytical quality, clinical validity, and test menu breadth of specialty reference laboratory hemato-oncology panels creates a service procurement relationship whose testing volume sustains above-average reference laboratory revenue growth. Labcorp's Oncology Testing Services, Quest Diagnostics' molecular pathology capabilities, and Mayo Clinic Laboratories' hematopathology specialization collectively define the U.S. reference laboratory hemato-oncology services landscape.

Assay kits and reagents are the fastest growing product segment because the expansion of in-house molecular pathology laboratories at comprehensive cancer centres, the commercial launch of FDA-approved companion diagnostic kit products for hematologic malignancy indications, and the growing consumption of NGS library preparation reagents and PCR amplification reagents from expanding clinical testing volumes create above-average kit and reagent revenue growth. Each academic cancer center that builds in-house NGS testing capability creates reagent consumption whose annual volume represents a structurally growing revenue stream. The regulatory approval of companion diagnostic kit products for targeted leukemia and lymphoma therapies creates new premium-priced assay kit categories whose per-test value exceeds standard laboratory reagent pricing.

By Technology, PCR dominates, NGS grows fastest

PCR retained the dominant technology position with approximately 32.14% of the hemato oncology testing market in 2025. PCR's combination of exceptional sensitivity, rapid result turnaround, regulatory approval status for validated companion diagnostic indications, and established clinical utility in BCR-ABL quantification for CML monitoring, JAK2 V617F detection in myeloproliferative neoplasms, and FLT3/NPM1 mutation detection in AML creates a broad clinical application base whose testing volume sustains dominant market position. Real-time PCR and digital PCR platforms' ability to quantify minimal residual disease at sensitivities below one tumor cell per 100,000 normal cells create the analytical capability that MRD-guided treatment protocols in CML, ALL, and acute promyelocytic leukemia require. The commercial availability of validated PCR-based companion diagnostic kits from QIAGEN, Bio-Rad Laboratories, and Thermo Fisher Scientific sustains clinical adoption across institutions whose regulatory compliance requirements favor validated commercial kit performance over laboratory-developed test alternatives.

NGS is the fastest growing technology because comprehensive genomic profiling's ability to identify the complete landscape of actionable mutations, copy number alterations, structural rearrangements, and gene fusions in a single test run creates diagnostic value that targeted single-gene PCR assays cannot provide. Each hematologic oncology treatment guideline update that adds a new targetable mutation to the treatment selection algorithm creates NGS testing demand from the clinical need to identify all actionable mutations simultaneously rather than through sequential single-gene testing. The commercial launch of FDA-approved comprehensive genomic profiling products targeting hematologic malignancy indications, including Foundation Medicine's Foundation One Heme, creates above-average NGS revenue growth from premium companion diagnostic test pricing.

By End-Use, hospitals dominate, academic and research institutes grow fastest

Hospitals retained the dominant end-use position with approximately 74.55% of the hemato oncology testing market in 2025. Each diagnosed hematologic malignancy patient whose treatment initiation requires molecular diagnostic workup creates a hospital-procured testing episode whose diagnostic value encompasses cancer subtype classification, actionable mutation identification, prognostic marker assessment, and MRD baseline measurement that concentrates commercially significant testing spend within hospital oncology services. The institutional oncology programme infrastructure, including clinical molecular pathology laboratories, hematopathology services, and multidisciplinary tumor board decision-making, creates a concentrated commercial testing environment that serves the highest clinical complexity patient population with the highest per-episode diagnostic testing value.

Academic and research institutes are the fastest growing end-use segment because investigational hemato-oncology testing in clinical trial protocols, biomarker discovery research programmes, and precision oncology research infrastructure investment create above-average testing volume growth that compounds with research funding growth. Each hematological oncology clinical trial that requires comprehensive genomic profiling of enrolled patient tumor samples creates research testing procurement whose per-patient volume substantially exceeds standard clinical testing. NCI-funded Cooperative Oncology Group clinical trials, academic precision oncology research programmes, and pharmaceutical company-sponsored companion diagnostic validation studies collectively sustain above-average academic and research institute testing volume growth.

Regional Analysis:

North America Hemato Oncology Testing Market Insights

North America dominated the global hemato oncology testing market in 2025, driven by the highest hematologic malignancy incidence, the most mature precision oncology adoption, the most extensive companion diagnostic regulatory approval framework, and the commercial headquarters presence of Illumina, Thermo Fisher Scientific, QIAGEN, Roche Diagnostics, and Guardant Health. The United States accounts for approximately 80.2% of North American revenues through its institutional oncology infrastructure, Medicare and private insurer molecular diagnostic reimbursement, and FDA companion diagnostic approval programme that sustain structured commercial testing investment.

Canada contributes approximately 19.8% of North American revenues through its provincial cancer agency networks including BC Cancer, Ontario Cancer Biomarker Network, and Institut national du cancer du Quebec whose centralized genomic profiling programmes create structured hemato-oncology testing procurement alongside Health Canada's companion diagnostic regulatory approval pathway.

Europe Hemato Oncology Testing Market Insights

Europe is a precision oncology-driven hemato-oncology testing market where the European Medicines Agency's companion diagnostic co-development requirements, national cancer center genomic profiling programmes, and healthcare system coverage decisions for molecular diagnostics collectively create a structured adoption framework. Germany accounts for approximately 24.1% of European revenues through its university hospital hematology department infrastructure, the German Cancer Consortium's genomic profiling programme, and Illumina's European manufacturing presence in Berlin.

The United Kingdom, France, and the Netherlands are significant secondary European markets where NHS England's Genomic Medicine Service, the Institut National du Cancer's precision oncology programme, and the Dutch national genomic diagnostic infrastructure create institutional hemato-oncology testing procurement. EDTA's European molecular diagnostic quality accreditation framework sustains analytical quality across European testing centres.

Asia Pacific Hemato Oncology Testing Market Insights

Asia Pacific is the fastest growing regional hemato oncology testing market, driven by China's extraordinary hematologic malignancy burden, India's rapidly expanding molecular diagnostic laboratory infrastructure, Japan's precision oncology investment, and South Korea's clinical genomics programme adoption. China accounts for approximately 46.3% of Asia Pacific revenues through its high leukemia and lymphoma incidence driven by environmental and demographic factors, the National Medical Products Administration's companion diagnostic approval programme, and major academic cancer center genomic profiling investment at institutions including Peking Union Medical College Hospital.

India represents the commercially fastest growing emerging market within Asia Pacific where the rapid private molecular diagnostic laboratory network expansion, growing hematologist awareness of precision oncology testing utility, and international pharmaceutical company clinical trial activity create above-average hemato-oncology testing volume growth. Japan's institutional precision oncology investment at the National Cancer Center Japan and South Korea's Yonsei Cancer Center sustain advanced hemato-oncology testing adoption.

MEA & Latin America Hemato Oncology Testing Market Insights

The UAE leads MEA revenues at approximately 30.8% through its premium private oncology center investment including Cleveland Clinic Abu Dhabi and King Hussein Cancer Center's hemato-oncology molecular diagnostic programme’s, complemented by Saudi Arabia's Vision 2030 oncology infrastructure investment. Brazil leads Latin American revenues at approximately 43.7% through INCA's national cancer programme, the Instituto do Cancer do Estado de Sao Paulo's genomic profiling capability, and private oncology laboratory network investment creating growing hemato-oncology testing procurement. Mexico's IMSS oncology programme and Colombia's private oncology center expansion collectively sustain regional market development through 2035.

Market Dynamics:

Growth Drivers: Rising hematologic malignancy prevalence and precision medicine companion diagnostic expansion

Rising hematologic malignancy prevalence is the hemato oncology testing market's most structurally significant growth driver. Blood cancers account for approximately 10% of all U.S. cancer diagnoses annually, with the Leukemia and Lymphoma Society documenting the disease burden that creates consistent diagnostic testing demand. Non-Hodgkin lymphoma's more than 500,000 annual global diagnoses, the global leukemia incidence of approximately 474,000 new cases annually, and the growing multiple myeloma incidence in ageing populations collectively create a growing diagnostic testing volume base whose precision medicine adoption amplifies per-patient testing value beyond what historical single-test diagnostic paradigms generated.

Precision medicine and companion diagnostic expansion is the market's most commercially significant value driver. Each new targeted hematologic oncology therapy that achieves FDA approval with a companion diagnostic requirement creates a mandatory testing pathway whose commercial value scales with the approved indication's patient population. The U.S. FDA's approval of more than 50 companion diagnostics for hematologic malignancies, the growing portfolio of CAR-T cell therapies requiring companion characterization, and the expanding IDH1/2, FLT3, BTK, and BCL-2 inhibitor therapy landscape collectively create a broadening companion diagnostic requirement base that sustains above-average hemato-oncology testing revenue growth through therapeutic pipeline progression.

Restraints: High testing cost and reimbursement access limitation

High cost of advanced molecular and genetic testing creates access barriers that moderate market growth in cost-constrained healthcare environments. NGS and multiplex PCR hemato-oncology panels typically cost between USD 1,000 and USD 5,000 per test, creating patient cost-sharing burdens and provider cost-benefit assessment requirements that delay adoption in resource-limited clinical settings. Inconsistent reimbursement policies, where Medicare and private insurers reimburse established PCR companion diagnostics but provide partial or no coverage for comprehensive genomic profiling panels and investigational biomarker assessments, create clinical adoption uncertainty that moderates the pace of NGS-based hemato-oncology testing integration into standard care protocols.

Opportunities: Liquid biopsy platform expansion and AI-driven diagnostic automation

Liquid biopsy technology expansion represents the hemato oncology testing market's most transformative near-term commercial opportunity. Circulating tumor DNA detection from peripheral blood samples in hematologic malignancies creates minimal residual disease monitoring, clonal evolution tracking, and treatment response assessment capabilities without the patient burden, complication risk, and sampling frequency limitations of repeat bone marrow biopsy. Guardant Health and Foundation Medicine's expansion of liquid biopsy platforms into hematologic malignancy indications, combined with the FDA's evolving regulatory guidance on ctDNA-based MRD assays, creates a structured pathway for next-generation liquid biopsy product commercialization that will expand hemato-oncology testing value significantly through the forecast period.

Recent Developments:

• 2024: Illumina expanded its TruSight Oncology 500 comprehensive genomic profiling panel in 2024 with enhanced coverage of hematological malignancy gene fusions and structural variants, supporting broader companion diagnostic application in lymphoma and leukemia treatment selection decisions at U.S. comprehensive cancer centres.

• 2024: QIAGEN launched next-generation Thera screen companion diagnostic kit enhancements in 2024 targeting expanded hematologic malignancy mutation panel coverage, supporting targeted therapy prescribing decisions across an expanded range of actionable genetic alterations in leukemia and myeloproliferative neoplasms.

• 2023: The U.S. FDA approved QIAGEN's therascreen FGFR2 RGQ RT-PCR Kit in 2023 for detection of genetic mutations in leukemia, providing companion diagnostic validation for targeted therapy prescribing decisions in hematologic malignancy that demonstrates the regulatory pathway maturation sustaining companion diagnostic investment.

• 2023: Foundation Medicine expanded FoundationOne Heme clinical validation in 2023 with enhanced NGS-based comprehensive genomic profiling coverage for hematologic malignancy, providing comprehensive actionable mutation identification supporting precision oncology prescribing decisions across leukemia, lymphoma, and multiple myeloma treatment programmes.

• 2023: Guardant Health initiated clinical validation studies in 2023 for liquid biopsy-based minimal residual disease monitoring in diffuse large B-cell lymphoma, establishing ctDNA-based MRD tracking as a complement to conventional imaging-based treatment response assessment in aggressive lymphoma treatment protocols.

Hemato Oncology Testing Market Key Players:

• Illumina Inc.

• Thermo Fisher Scientific Inc.

• QIAGEN NV

• Roche Diagnostics GmbH

• Bio-Rad Laboratories Inc.

• Abbott Laboratories

• Becton Dickinson and Company

• Guardant Health Inc.

• Foundation Medicine Inc. (Roche)

• Invitae Corporation

• Agilent Technologies Inc.

• Sysmex Corporation

• Genomic Health Inc. (Exact Sciences)

• NeoGenomics Laboratories Inc.

• Labcorp Oncology

• Myriad Genetics Inc.

• Burning Rock Biotech Ltd.

• SOPHiA GENETICS SA

• Tempus AI Inc.

• Caris Life Sciences Inc.

Hemato Oncology Testing Market Report Scope: